Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ornithine Aketoglutarate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.52 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.52 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 2/20 | 0.82 |
| ▸ | ARG2 | P78540 | 4/20 | 0.57 |
| ▸ | ARG1 | P05089 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ornithine Aketoglutarate SCHEMBL534810 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 | |
| Ornithine Aketoglutarate SCHEMBL28741424 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 | |
| Ornithine SCHEMBL4813611 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 | |
| Ornithine Aketoglutarate SCHEMBL28849602 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 | |
| Ornithine SCHEMBL296380 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 | |
| D-Ornithine SCHEMBL8046629 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 | |
| Ornithine SCHEMBL15016118 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 | |
| D-Ornithine SCHEMBL4813616 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 | |
| D-Ornithine SCHEMBL377431 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 | |
| Ornithine SCHEMBL18338950 | 1.00 | GSR (0.82) | GSRARG2ARG1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795650-B1 | ADHESIVE COMPOSITION, AND METHOD FOR PREPARING SAME | CJ CHEILJEDANG CORP (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-12410341-B2 | Adhesive composition, and method for preparing same | CJ CHEILJEDANG CORPORATION (KR) | 2025-09-09 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| CN-112334556-B | Adhesive composition, preparation method thereof and adhesive product containing same | CJ第一制糖株式会社 | 2022-12-13 | — | — | CN | disclosed |
| US-20210189180-A1 | ADHESIVE COMPOSITION, AND METHOD FOR PREPARING SAME | CJ CHEILJEDANG CORPORATION (KR) | 2021-06-24 | — | — | US | disclosed |
| EP-3795650-A1 | ADHESIVE COMPOSITION, AND METHOD FOR PREPARING SAME | CJ Cheiljedang Corporation (KR) | 2021-03-24 | — | — | EP | disclosed |
| CN-112334556-A | Adhesive composition and method for preparing the same | CJ第一制糖株式会社 | 2021-02-05 | — | — | CN | disclosed |
| EP-3634943-B1 | METHOD FOR PREPARATION OF DIFLUOROMETHYLORNITHINE | LONZA AG (CH) | 2020-09-09 | — | — | EP | disclosed |
| US-20200148627-A1 | METHOD FOR PREPARATION OF DIFLUOROMETHYLORNITHINE | LONZA LTD (CH) | 2020-05-14 | — | — | US | disclosed |
| EP-3634943-A1 | METHOD FOR PREPARATION OF DIFLUOROMETHYLORNITHINE | Lonza Ltd (CH) | 2020-04-15 | — | — | EP | disclosed |
| WO-2004022536-A1 | NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-03-18 | — | — | WO | disclosed |
| CN-1372540-A | Non-hydroscopic salts of active ingredients having therapeutical and/or nutritional activities and orally administrable compositions containing same | BIOSALTS SRL (IT) | 2002-10-02 | — | — | CN | disclosed |
| US-6083496-A | PURE COMPETITIVE INHIBITORS OF NATURAL POLYAMINE TRANSPORT IN MAMMALIAN CELLS; USED TO EVALUATE ANTITUMOR EFFICACY OF POLYAMINE DEPLETION STRATEGIES WITH MINIMAL SYSTEMIC CYTOTOXIC EFFECTS OR TO CONTROL AND TREAT DISORDERS INVOLVING | UNIVERSITE LAVAL (CA) | 2000-07-04 | — | — | US | disclosed |
| EP-1003715-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999054283-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 1999-10-28 | — | — | WO | disclosed |
| EP-0876327-A2 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998017623-A2 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (US) | 1998-04-30 | — | — | WO | disclosed |
| WO-1994012480-A1 | 1,3-DIAZACYCLOALKYL OXIME DERIVATIVES | AKZO NOBEL N.V. (NL) | 1994-06-09 | — | — | WO | disclosed |
| US-4652519-A | Bifunctional chelating agents and process for their production | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1987-03-24 | — | — | US | disclosed |
| US-4234744-A | Process for the production of aminoacid hydrochlorides/or diaminoacid dihydrochlorides | DEUTSCHE GOLD- UND SILBER SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148627-A1 | METHOD FOR PREPARATION OF DIFLUOROMETHYLORNITHINE | SMYD3, MCM3, HLCS | GRIN2D 2162/4885GRIN3B 2774/4885GRIN1 4125/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | GRIN2D 4117/4885GRIN3B 3486/4885GRIN1 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.